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Vaccines are regarded as the safest and most cost-effective strategy to prevent 
infectious diseases. For some diseases, vaccine improvements are required as protection levels 
are still inadequate. The key to solving this challenge might lie in the development of more 
efficacious vaccine delivery systems and adjuvants. Poly (lactide-co-glycolide) (PLGA) is a 
biodegradable polymer which has an extensive safety record in biological systems and 
possesses immunological adjuvant properties as injectable particles. In the present work, 
micro- and nanoparticles of PLGA and PLA were explored as a vaccine delivery system in 
Atlantic salmon (Salmo salar). The overall objectives were to investigate their adjuvant 
abilities in provoking innate and adaptive immune responses, forming antigen depots and 
inducing protective immunity in a challenge test with infectious pancreatic necrosis virus 
(IPNV).      
Formulation parameters in preparation of polymeric particles were systematically 
optimized (paper IV) to achieve stable PLGA particle products containing co-entrapped 
model antigens and β-glucan (paper I and II), or virus particles of infectious pancreatic 
necrosis virus (IPNV) (paper III). Post immunization potency of nanoparticles (300-400 nm) 
was demonstrated by their ability to induce early innate responses (day 2, 4 and 8) at 
transcription levels equal to or higher than the oil-adjuvanted formulation (paper I). Temporal 
differences in expression levels of innate markers were observed, suggesting rapid systemic 
distribution of particles (paper I). By tracing of isotope labelled proteins, nanoparticles (˂ 
1000 nm) were found to localize antigens in the head kidney while micro-sized (~ 8 µm) 
particles generally retained antigen at the injection site. Irrespective of size, particles made of 
polymers with high molecular weight (MW) generally had superior depot capabilities 
compared to their low MW counterparts (paper II). Adaptive immune responses to 
immunization were assessed by QPCR and ELISA. T cell markers were not differentially 
expressed at the selected early time points (paper I), but at day 60 and 75 antibody responses 
were found to be elevated (paper II and III). In a dose-response study, micro- but not 
nanoparticles were demonstrated to be equally potent compared to the oil-adjuvanted control 
group with regard to induction of antibody responses. Long-term antibody responses induced 
by particles were generally less robust and therefore declined towards the end of the 
experimental period (120 days), while responses induced by the oil-adjuvanted formulation 
progressively increased. Following immunization, antibody responses were not related to 
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polymer qualities or the ability of particles to depot or distribute antigens. Scoring of side 
effects demonstrated excellent safety profiles for the particle formulations (paper II and 
discussed in paper V). In paper III, vaccine efficacy was tested in a cohabitation challenge 
with IPN. Survival rates for the nanoparticle vaccinated groups were comparable to the non-
vaccinated control fish and demonstrated that their ability to induce protection against IPN 
was inferior to the oil-adjuvanted vaccines. Virus re-isolation from head kidney and blood 
during the challenge period did however demonstrate some level of protection as the 
nanoparticle vaccinated groups were able to delay the IPNV infection.  
 
In the presented studies, the principal adjuvant properties of PLGA particles in 
Atlantic salmon have been demonstrated to include their capacity to induce strong innate 
responses and provide antigen depots for long-term delivery of antigens. In addition, 
indication of particle presence in lymphoid organs was an interesting finding that could 
suggest a certain targeting effect to phagocytic cells. To achieve a better understanding of 
how PLGA particles may be used to direct immune responses in salmon, more detailed 



















          Vaksiner er ansett som den sikreste og mest kostnadseffektive strategien for å 
forebygge smittsomme sykdommer. Mot noen sykdommer er beskyttelsen etter vaksinering 
fremdeles uttilstrekkelig og forbedringer av vaksinen nødvendig. Nøkkelen til å løse denne 
utfordringen kan ligge i utvikling av mer effektive vaksineleveringssystemer og adjuvanser. 
Poly (laktid-co-glykolid) (PLGA) er et nedbrytbart polymer som i en rekke studier har vist 
seg å være svært kompatibelt med bruk i biologiske systemer, samtidig som injiserbare 
partikler av PLGA innehar viktige immunologiske adjuvantegenskaper. I dette arbeidet har 
mikro-og nanopartikler av PLGA og PLA blitt utforsket som et alternativt vaksinekonsept til 
atlantisk laks (Salmo salar). Hensikten med arbeidet var blant annet å undersøke partiklenes 
evne til å framprovosere innate (medfødte) og adaptive immunresponser, fungere som 
antigendepoter og indusere beskyttende immunitet i en smittetest med infeksiøs pankreas 
nekrose virus (IPNV). 
          Ved en systematisk tilnærming ble formuleringsparametrene for produksjon av partikler 
optimalisert (artikkel IV) for å oppnå stabile PLGA partikler inneholdende modellantigener 
og β-glukan (artikkel I og II), eller viruspartikler av infeksiøs pankreas nekrose virus (IPNV) 
(artikkel III). Nanopartikler (300-400 nm) viste seg å være svært effektive i å indusere innate 
immunresponser (dag 2, 4 og 8 etter immunisering). På transkripsjonsnivå (mRNA) var 
responsene like eller høyere enn responsene etter immunisering med en olje-adjuvans 
(artikkel I). Temporale forskjeller i uttrykket av innate markører ble observert, noe som 
antydet rask systemisk distribusjon av partikler (artikkel I). Bruk av isotopmerkede proteiner 
viste at nanopartiklene (˂ 1000 nm) i stor grad bidro til å lokalisere antigenene til hodenyren, 
mens mikropartiklene (~ 8 µm) generelt holdt antigenet igjen på injeksjonsstedet. Uavhengig 
av partikkelstørrelse hadde partikler laget av polymerer med høy molekylvekt (MW) større 
kapasitet til deponere antigener i forhold til partikler laget av polymerer med lav MW 
(artikkel II). Adaptive immunresponser ble analysert ved bruk av QPCR og ELISA. QPCR-
analyser viste at T-cellemarkørene ikke ble oppregulert i hodenyren eller milten de første 
dagene etter immunisering (artikkel I), men ved dag 60 og 75 var antistoffresponsene forhøyet 
sammenliknet med den negative kontrollgruppen (artikkel II og III). I et dose-respons studie 
ble mikro-, men ikke nanopartikler vist å være like potent i forhold til olje-adjuvansen med 
hensyn til induksjon av antistoffresponser. Antistoffresponsene etter immunisering med 
partikler var generelt mindre robuste i forhold til etter immunisering med en olje-basert 
adjuvans, hvor antistoffresponsen gradvis økte i løpet av den eksperimentelle perioden (120 
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dager). Antistoffresponser kunne generelt ikke er relateres til egenskaper ved polymeret eller 
partiklenes evne til å deponere eller distribuere antigener. Evaluering av bivirkninger i 
bukhulen etter immunisering med nano- og mikropartikler viste at disse formuleringene 
forårsaker svake eller ingen sammenvoksninger, men at melanindeponeringen er noe høyere i 
forhold til hos uvaksinert fisk (artikkel II og diskutert i artikkel V). I artikkel III ble 
vaksineeffekt testet i et kohabitantstudie med IPN. Overlevelsen for de gruppene som ble 
vaksinert med nanopartikler var sammenlignbare med den uvaksinerte kontrollgruppen og 
resultatene viste dessuten at partiklenes evne til å indusere beskyttelse mot IPN var dårligere 
enn beskyttelsen etter vaksinering med en inaktivert helvirusvaksine med olje-adjuvans. Re-
isolering av virus fra hodenyren og blod i løpet av smitteperioden viste imidlertid at 
nanopartiklene hadde noen grad av beskyttelse ettersom disse gruppene var i stand til å utsette 
IPNV infeksjonen. 
 
          Studiene i denne avhandlingen viser at adjuvantegenskapene PLGA partikler har ved 
immunisering av atlantisk laks inkluderer deres evne til å indusere sterke innate responser og 
deponere antigener for langtidseksponering til immunceller. Indikasjon på tilstedeværelse av 
partikler i lymfoide organer er et interessant funn som antyder at partiklene kan benyttes til 
målrettet levering av antigener til fagocyttiske celler. For å oppnå en bedre forståelse av 
hvordan PLGA partikler kan benyttes til å dirigere immunresponsen hos laks, bør fremtidige 
















During the last century, animal farming of both terrestrial and aquatic species has gone 
through a change from small businesses run by farmers and their families, to large scale 
production facilities with fewer owners, high production volumes and increased animal 
densities. The transition to the industrialized husbandry has constituted a challenge to farmers 
regarding preservation of the many aspects of animal welfare, specifically with regard to 
adaptation of prophylactic measures to limit the spread and outbreak of contagious diseases. 
Although the concept of vaccination originated more than 200 years ago, passive 
immunization and the use of antibiotics and chemotherapeutics has dominated disease 
prophylaxis and treatment in veterinary medicine until more recent decades. Acquired 
knowledge in virus propagation and adjuvant technology the last 50 years has albeit 
demonstrated that the basis for mass vaccination of farmed animals is present, cost-effective 
and a prerequisite for sustainable food production. 
The Norwegian salmon farming industry was established during the 1960s and `70s. 
Salmonids (rainbow trout and Atlantic salmon) had favourable biological and behavioural 
conditions for farming, but while the technological challenges for husbandry were affordable, 
high production volumes remained absent due to outbreak of contagious bacterial diseases 
such as furunculosis (Aeromonas salmonicida) and vibriosis (Vibrio salmonicida
(*)
 and V. 
anguillarum). Immersion and injection vaccines based on inactivated bacteria were initially 
tested on rainbow trout in 1977 and later in Atlantic salmon. Still, in the following years 
bacterial diseases became recurrent setbacks for the industry, an experience which is well 
reflected in the statistics over the use of antibiotics at that time (almost 50 metric tons in 1987 
while fish production was merely 50 000 metric tons). It was not until an oil-based adjuvant 
was included in an injection vaccine during the late 1980s that the vaccines became potent 
enough to confer immunity against the aforementioned diseases. Today the annual Norwegian 
production volume of salmonids is close to 1 million metric tons (2010), a number that 
corresponds to about 250 million salmonids being vaccinated every year. The correct use of 
highly efficacious vaccines has reduced the use of antibiotics in salmonid farming by 99.8 %.  
The prescribed antibiotics the last years has mainly been to treat diseases in Atlantic cod, a 
species relatively new in the context of fish farming where vaccines still are in development. 
It is obvious that the use of vaccines during the last three decades have been important 




 In more recent years, intracellular pathogens have increasingly become a resource-
intensive challenge. The oil-based adjuvant that so far has been a successful additive in 
vaccines seem to fell short in conferring protective immunity against some viral and 
intracellular bacterial diseases. Perhaps the best example in this context is the vaccine against 
infectious pancreatic necrosis (IPN). It was the first commercial viral vaccine for salmon to be 
introduced in the Norwegian marked in 1995. Even after years of research and optimization, 
the vaccines still only demonstrate sub-optimal protection and in 2009 alone, 223 outbreaks of 
IPN were recorded in Norway. With most of the bacterial diseases largely under control due 
to vaccination using oil-based adjuvants, the current challenge in vaccine development for the 
salmon aquaculture industry is to design and mass produce vaccine adjuvants and delivery 
systems that are able to mount robust immune responses and provide long-term herd 
immunity against intracellular pathogens. The recent characterization of emerging pathogens 
in salmonids, such as piscine myocarditis virus (PMCV) and piscine reovirus (PRV) 
(etiological agents for cardiomyopathy syndrome (CMS) and heart and skeletal muscle 
inflammation (HSMI), respectively) adds weight to this notion and emphasizes the need to 
search for novel vaccine concepts for future vaccinologists to be one step ahead of the 
pathogen. 
 
 “…may I not with perfect confidence congratulate my country and society at large on 
their beholding; in the mild form of the Cow Pox, an antidote that is capable of extirpating 
from the earth a disease which is every hour devouring its victims; a disease that has ever 
considered as the severest scourge of the human race!”  
 
Final words by Edward Jenner (1749-1823) in  








Even though vaccinology and immunology are different scientific disciplines they are 
found on the same branch in science and share a common goal; to understand how foreign 
substances affect the immune system. The current work combines the two fields in its 
presentation of a vaccine concept which still is considered novel in the context of fish. By 
mainly referring to experiments on higher vertebrates, the following introduction therefore 
aims to give some background on the vaccine delivery system and provide insight into how its 
characteristics may be used to affect and direct the immune responses in teleosts, with 
emphasis on salmonids.  
AN INTRODUCTION TO FISH IMMUNOLOGY 
          Fish is a paraphyletic group of organisms consisting of almost 32 000 identified 
species
1
, including about one hundred species of jawless hagfish and lampreys [1]. Fish have 
a unique evolutionary position as the most primitive of the vertebrates [2] and 400-500 
million years ago it was the first animal phyla to possess both innate and adaptive immunity. 
Although fish have full representation of the fundamental components of the immune system, 
the level of sophistication appears to be somewhat different compared to mammals. The 
suggested trend is that the innate immunity is highly involved and richly diversified, while the 
adaptive immunity is less evolved and possibly less flexible [3]. As pointed out in two recent 
reviews by Whyte [4] and Magnadottir [5] the innate responses in fish may be considered 
vital due to both the late ontogenic appearance of the adaptive parameters in many species and 
the fact that the poikilotermic nature of fish may constrain the adaptive immune response.     
 
          The most apparent differences between the structure of the immune system of mammals 
and fish are the anatomical distribution of lymphoid tissues and the fact that fish lack lymph 
nodes and bone marrow. In teleosts the major lymphoid organs include the spleen, head 
kidney, thymus and the primitive gut/mucosa-associated lymphoid tissues (G/MALTs) as well 
as the recently described interbranchial lymphoid tissues [6-8]. The spleen and head kidney 
are known as filtering organs in the vascular system, removing effete blood cells and foreign 
agents, in addition to inducing and elaborating immune responses [9]. Due to their capacity to 
trap and present soluble and particulate antigens from the circulation, both these organs are 
                                                 
1
 Information retrieved from http://www.catalogueoflife.org/col/details/database/id/10 (12.12.2011) 
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considered lymph node analogues (secondary lymph organs) [10;11]. Furthermore, the head 
kidney is regarded a primary lymphoid organ because of its hematopoietic function and 
morphological similarities to the bone marrow found in higher vertebrates [4], and it is also 
the major site for B-cell development and antibody production [12]. Similar to other 
vertebrates the teleost thymus is considered the primary lymphoid organ for T-cell 
development [13;14] although T-cells have been suggested to assemble and aggregate in other 
tissues [8;15].  
          Like in mammals, the innate (inherited) immune system is divided into physical 
(epithelial/mucosal) and mechanical barriers, cellular components and humoral parameters 
(Table 1). In fish, the epithelial and mucosal linings are important portals of entry for 
pathogens as fish live in direct contact with their surroundings. Because of this, the skin, 
alimentary tract and gills contain numerous humoral defense parameters such as antimicrobial 
peptides (AMPs), immunoglobulins (Igs), complement factors, pathogen recognition receptors 
(PRRs) and cytokines [4;16-20] that exist either in soluble form or expressed as cellular 
receptors. Natural antibodies (immunoglobulins) in the form of IgM in teleosts, have been 
described in a number of fish species and are known to play a key role in the innate immune 
response [21-23]. A range of inflammation induced acute phase proteins (APPs) including 
C-reactive protein, serum amyloid P, lysozyme, transferrin and thrombin have been identified 
in teleosts, where hepatocytes are considered the primary source [24]. The APPs also 
comprise the complement system, which has a vital role in innate immunity by mediating 
phagocytosis, respiratory burst, chemotaxis and cell lysis [25] and on the adaptive immunity 
by augmenting B-cell proliferation [26]. All three complement pathways (alternative, lectin 
and classical) are well developed in fish and may result in the membrane attack complex 
(MAC), cell lysis and phagocytosis by opsonization. An important feature of the teleost 
complement system compared to what is found in mammals is the existence of several C3 
subtypes with functional and structural diversity [27]. Furthermore, it has been suggested that 
cells of the monocyte-macrophage lineage do not express C3 [28]. 
          Of the pattern recognition receptors (PRRs), the Toll-like receptor (TLR) family has 
been extensively studied in fish as these transmembrane proteins are regarded crucial in the 
detection of conserved structures on pathogens, collectively called pattern associated 
molecular patterns, or PAMPs [29]. The TLRs are clustered in two broad groups depending 
on the basis of their agonists; the TLRs responding to extracellular stimuli (e.g. TLR2 – 
peptidoglycan, TLR4 – lipopolysaccharides (LPS), TLR5 – flagellin) are located on the cell 
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surface, while the intracellular TLRs that recognize dsRNA and unmethylated CpGs include 
TLR3, 7, 8 and 9 and are located on the inner surface of endosomes [30]. The ability to 
distinguish among classes of pathogens makes the TLRs highly important in the orchestration 
of an appropriate acquired immune response. At least 16 different TLR types have been 
identified in fish, including 6 non-mammalian TLRs, and the agonist recognition induces 
cytokine expression similar to that observed in mammals [31-33]. Other widely used immune 
stimulating agonists in fish are β-glucans derived from bacteria, yeast and algae. The 





Table 1. Summary of the main components of the innate and adaptive immune system in teleosts [4;24;34] . 
Immune system 
division 
Immune system component Effector mechanism 
Innate Epithelial and mucosal linings; 
skin, alimentary tract and gills 
First line of defense; physical barrier 
 Humoral parameters Antimicrobial peptides (AMPs), natural antibodies, 
the complement system and other acute phase 
proteins (C-reactive protein, serum amyloid P, 
lysozyme, transferrin and thrombin ), associated 
cytokines, cellular receptors (PRRs). 
 Cellular components Granulocytes, non-specific cytotoxic cells (NCCs), 
monocytes/macrophages,  





 T-helper lymphocytes (Th-cells) 
Associated cytokines 
 Humoral B-lymphocytes  
IgM, IgD, IgT and IgZ antibodies 
Associated cytokines 
Lymphoid tissues Primary Head kidney (B lymphopoiesis) and  
thymus (T lymphopoiesis) 
 Secondary Head kidney and spleen  
 Other Gut- and mucosa-associated lymphoid tissues 
(GALTs/MALTs) 
Interbranchial lymphoid tissues (ILTs)  
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receptors, complement receptor 3, dectin-1 and TLR2/6 in mammals [35]. β-glucan receptors 
have been found in teleosts [36;37], but their receptor family affiliation remains to be 
elucidated.  
          The cellular arm of the innate components in teleosts includes cells that are 
morphological and functional equivalent to mammalian monocytes(B7
+
)/macrophages, 
granulocytes (neutrophils, eosinophils and basophils), thrombocytes and natural killer cells 
[4;6;38-40]. In addition, cells showing morphological similarities and expression of genes 
associated with dendritic cell (DC) function and antigen presentation have recently been 
described in zebrafish [41]. Of the innate cells, the defense primarily involves phagocytic 
(neutrophils and monocytes/macrophages) and nonspecific cytotoxic cells (NCCs). 
Phagocytosis followed by antigen presentation to adaptive immune cells, is central in 
mitigation and eradication of pathogens and is known to be a vital event that bridges the 
innate and the adaptive immune systems by certifying the development of a pathogen specific 
adaptive response. In mammals antigen presenting cells (APCs) are well described and 
include monocytes, macrophages, B-cells, classical dendritic cells (DCs) and plasmacytoid 
DCs [42]. However, in teleosts the macrophages are still regarded the most important 
professional cell in antigen processing and MHC II presentation, even though neutrophils and 
B-cells have been demonstrated to possess phagocytic activity [43;44].  
          Appearance of the thymus, the B- and T-lymphocytes and the RAG (recombination 
activation gene) enzymes are regarded as imperative for the evolution of the adaptive 
immune system as gene rearrangements offers an almost unlimited diversity in pathogen 
recognition. It is well established that all the basic features of the adaptive arm of the teleost 
immune system exist and that its initiation primarily relies on the ability of non-self 
discrimination and recognition performed by the innate components. T-lymphocytes in 
mammals are defined by expression of different cluster of differentiation (CD) glycoproteins 
and include effector and regulatory cells such as CD8
+ 
cytotoxic T-lymphocytes (CTL) and 
CD4
+ 
T-helper (Th) cell subsets known for their plasticity (Th1/Th2/Th9/Th17/induced 
regulatory T cells (iTreg)/T cell help for B cells (Tfh)) [45-48]. In some teleosts, T-cell 
related genes such as GATA-3, Foxp3, T-bet, TCR, CD3, CD28, CD4 and CD8 in addition to 





 Th cells in fish are similar to those found in higher vertebrates. 
Fundamental assumptions have, however, been questioned with the recent finding of an 
distinctive immune system in Atlantic cod (Gadus morhua) where multiple MHC I genes and 
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unique composition of TLR families apparently compensate for the absence of MHC II and 
CD4 genes essential for a Th2 response [54]. Recently, a series of functional studies using 
monoclonal antibodies (mAbs) on teleost T-cells have demonstrated that allogeneically 
distinct leukocytes (assumed to be several types of APCs) were able to induce proliferation of 
CD4
+
 lymphocytes followed by proliferation of CD8
+
 lymphocytes [55] and that CD8
+
 
lymphocytes are the principal cell involved in cell-mediated cytotoxicity [56;57]. 





 T lymphocytes were found to be similar in teleosts and mammals, 
although the low abundance of CD8
+
 T cells in blood and distribution to the respiratory tissue 
may reveal a distinct dynamic in teleosts [8;58;59].   
 
          B-lymphocyte derived specific antibodies expressed either as receptors or secreted in 
plasma are key humoral parameters of the adaptive immune system. In general, the antibody 
repertoire of teleosts is regarded as more restricted compared to the mammalian counterpart 
[60]. Most importantly, the genetic organization of teleost Ig does not allow for class-
switching, thus B-cells only express and secrete the IgM class, which is a trait similar to the 
B1 cells found in mammals. A fundamental characteristic of the teleost IgM is the tetrameric 
organization (pentameric organization in mammals) and the more loosely and flexible 
association of the monomers. Recent studies have also demonstrated the existence of other 
immunoglobulin isotypes, namely IgD [61;62], IgT [63] and IgZ [64]. As a response to 
vaccination, immunization or infection most teleosts mount strong antibody responses, 
however the lag period is known to be 4-10 weeks (species and temperature dependent) 
before significant levels can be detected, and antigen affinity and antibody heterogeneity are 
lower than those found in mammals [65]. In Atlantic cod and other species within the same 
family the humoral responses are described as weak and barely detectable after immunization, 
even though immunization with bacteria-derived antigens may induce protective immunity 
[66;67]. Immunological memory and initiation of secondary responses to previously 
encountered immunogens have been described as moderate or absent in teleosts [68], and the 
main reason for this could be ascribed to the lack of Ig class switching during second 
exposure, in concert with other factors such as slow metabolic rate and the absent of lymph 
nodes or germinal centers [34]. 
          As a language between cells, cytokines (interleukins (ILs), interferons (IFNs) and 
chemokines) are known to bridge the innate and adaptive immune system and contribute to 
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tune and induce a pertinent response upon pathogen encounter. The lack of appropriate 
antibodies has so far limited research on teleost cytokines at the genetic (mRNA) level, 
although the biological activity of some central cytokines has been described [69-71]. 
However, their importance in the understanding of the teleost immune system is well reflected 
in the range of cytokines so far described at a genetic level, including features linked to 
inflammation (IL-1β, TNF-α, IL-2, IL-6 (acute phase), IL-8 (CXC chemokine), IL-17, IL-18), 
T-cell differentiation (IL-2, IL-4, IL-12), T-cell memory (IL-7, IL-15), viral 
persistence/survival factor for B and T cells (IL-21), antiviral defense (type I (IFNα(a)/β(b)) 
and II ((IFN-γ(g)/ IFN-γrel)) and anti-inflammation (IL-10), as reviewed in [40;72-76]. 
 
          To sum up this section on fish immunology, the current understanding of the teleost 
immune system is that most of the qualities found in the immune system of higher vertebrates 
have an equivalent in one form or the other in teleosts. Even though there are species-to-
species variations among teleosts, the basis for antigen recognition and initiation of the 
adaptive apparatus is tailored to enable effective eradication of invading pathogens, a quality 
which is fundamental for vaccinologists.  
 
 
Vaccines and vaccination 
          A vaccine may be defined as “a preparation of microorganisms or their antigenic 
components which can induce protective immunity against the appropriate pathogenic 
bacterium or virus but which does not itself cause disease” [77] or simply as “a dead or 
attenuated (non-pathogenic) form of the pathogen” [78]. In addition to the immunogenic 
components, vaccines consist of an adjuvant/delivery system that aid in induction of innate 
and adaptive responses, and stabilizers/surfactants which contribute to the 
formulation/immunogens staying intact during storage and administration. In general, 
vaccines are further sorted in a number of sub-categories mainly based on the condition of the 
antigen. These include heat- or formalin inactivated whole microorganisms, 
antigen/immunogen sub-units (peptides, proteins, toxoids and its conjugates) and 
live/replicating/attenuated microorganisms, as well as plasmid DNA (pDNA) vaccines 




ADJUVANTS AND VACCINE DELIVERY SYSTEMS 
          As the majority of non-living vaccines are relatively poor inducers of adaptive 
immunity, adjuvants (from the Latin word adjuvare, meaning “to help” or “aid”) are essential 
components of most clinically used vaccines. In a broad sense, adjuvants comprise all 
substances that are able to accelerate, reinforce, improve or modify the effect of other agents 
(in vaccinology other agents refer to the antigen). Adjuvants are needed in a vaccine for 
various purposes, the foremost being to enhance the immunogenicity of highly purified or 
recombinant antigens and/or reduce the amount of antigen or the number of immunizations 
needed for protective immunity. Classification on chemistry and structure allocates vaccine 
adjuvants in two broad groups mainly based on their particulate and non-particulate nature 
[79]. Vaccine delivery systems are generally particulate adjuvants and comprise constructs 
such as emulsions (oil-in-water (e.g. MF59) and water-in-oil (Freund’s adjuvant)), mineral 
salts (Al (OH)3), liposomes, virus-like particles (VLPs), immune stimulating complexes 
(ISCOMs of saponin and lipid matrixes) and nano- and microparticles of chitosan, alginate 
and poly (lactide-co-glycolide) (PLGA) [80-86]. Non-particulate adjuvants are single 
compounds with intrinsic immunomodulatory and/or immunostimulant properties that 
generally benefit from association with a particulate adjuvant [79]. These include pathogen-
derived products (e.g. lipopolysaccharides (LPS), unmethylated CpGs, myramyl dipeptide 
(MDP) and flagellin), carbohydrate products (e.g. β-glucan), synthetic products (double 
stranded RNA (poly I:C)) and endogenous immunostimulatory therapeutics such as cytokines 
[87]. For vaccines based on whole microorganisms, such as inactivated or live vaccines, a 
number of the non-particulate pathogen derived adjuvants are integrated as a natural part of 
the vaccine (e.g. flagellin found on bacteria or dsRNA in viruses). 
 
ADJUVANT MECHANISM OF ACTION 
          Adjuvants were originally described as substances that when used in combination with 
a specific antigen would “produce a more robust immune response than the antigen alone” 
[88]. Even though the use of adjuvants has a long history, their exact mechanism of action is 
poorly understood as the effect of adjuvants mainly has been proven empirically. The general 
understanding is that adjuvants improve the immune response to vaccine antigens by; (1) 
increasing the immunogenicity of highly purified or recombinant antigens and thereby reduce 
the dose of antigen needed; (2) enhancing the magnitude, speed and duration of the immune 
response; (3) modulating antibody avidity, specificity, isotype or subclass distribution; (4) 
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stimulating CTL responses; and/or (5) generating antigen depots and/or pulsed antigen release 
[79;87;89]. In addition, the recognition of non-self [90] and tissue disruption caused by the 
vaccine matrix together provide exogenous and endogenous danger signals [91], respectively, 
that calls into action innate effectors able to prime T cells and thereby initiate appropriate 
adaptive responses. Moreover, administering antigens and adjuvants separately is known to 
result in considerably lower responses compared to co-injection, suggesting that the adjuvant 
effect is more synergistic than additive.   
          On a cellular level, vaccine recognition and subsequent initiation of appropriate 
responses are largely based on three signals. The most central signal is the antigen (signal 1), 
which provides the information required for development of specific immunity. Furthermore, 
co-stimulatory (signal 2) molecules via receptor-ligand interaction between APCs and T-cell 
antigens are required to avoid anergy and abortive responses. To activate APCs and orientate 
the Th response, an additional mandatory signal 0 is necessary. Signal 0 is mostly induced 
through the recognition of PAMPs including TLRs by PRRs. Depending on where the 
adjuvant acts on the recipient cell, adjuvants have been proposed to be categorized as type A, 
B or C [92]. Most of the recently developed receptor-specific immunomodulatory adjuvants 
such as TLRs ligands are categorized as type A, while the particulate adjuvants (i.e. vaccine 
delivery systems) are type B as they enhance antigen presentation to T cells by improving 
MHC conversion [79]. In this category, formulations such as liposomes, PLGA particles and 
oil emulsions are found. Type C adjuvants comprise adjuvants of endogenous origin that 
directly enhance signal 0 (e.g. cytokines). In brief, recognition of both the antigen and TLRs 
by APCs is required for optimal antigen processing and initiation of the innate, and 
subsequently the adaptive responses. Furthermore, several studies have demonstrated 
synergistic effects and increased vaccine potency by co-delivery of type A and type B 
adjuvants [93-96].  
          One of the first qualities to be described for adjuvants were their ability to depot 
antigens [97]. A depot ensures local retention of the antigen at the injection site and prolongs 
exposure of the immunogenic cargo to APCs. This quality is also assumed to be one of the 
central success factors of the oil emulsions used in salmon vaccines [98] and in addition to the 
powerful adjuvant properties it has contributed to make revaccination unnecessary. As 
mentioned previously, the immune response in fish may be hampered by a slow metabolic 
rate, and as a consequence this may influence the rate at which the immune response is 
mounted and make the antigen persistence necessary for an adaptive immune response to be 
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initiated before the antigen is cleared. Recent studies on the mechanism of action for the 
widely used alum and MF59 in humans have demonstrated that these adjuvants induce 
secretion of chemokines, which provides an immunocompetent micro-environment resulting 
in successive waves of infiltrating cell populations, with neutrophils being the first and most 
abundant, followed by inflammatory monocytes, eosinophils and DCs [99-101]. Similarly, in 
a study whereby salmon were injected intraperitoneally with an oil based vaccine, the early 
inflammatory responses were demonstrated to occur 1-2 weeks after vaccination and 
recognized by infiltration of neutrophils to the peritoneal cavity. During the next four weeks 
post immunization the number of neutrophils declined, while macrophages became more 
prominent. At even later time points (12-16 weeks) after vaccination, the number of 
lymphocytes increased [102]. In another study by the same authors, a steady decrease of the 
quantity of antigens was observed at the injection site from 3 to 12 months post vaccination 
[103]. Other studies have demonstrated that antigens accumulate in the head kidney and 
spleen [11;104], and durable persistence has been reported in the head kidney [11;104;105]. 
Together these studies demonstrate that antigen processing and clearance from oil based 
vaccines are consuming and possibly results in a sustained net transport of antigens to 
lymphoid organs. Drainage of antigens to lymph nodes has also been shown to be one of the 
adjuvant properties of the aforementioned MF59 and alum [99].  
          One of the long-term effects of vaccination of salmon with oil based formulations is the 
formation of classical immune granulomas where oil droplets and antigens are surrounded by 
macrophages intermixed with a few lymphocytes [103]. It has been speculated if granulomas 
serve as lymph node analogues as they provide a focal site for concurrent presence of innate 
and adaptive immune cells in a local cytokine micro-environment [98].  
 
VACCINE EFFICACY AND SAFETY 
          The in vivo usability of commercially available vaccines for fish is primarily tested and 
documented on the basis of two main considerations. These include efficacy
2
 (ability to 
reduce mortality and pathology, delay onset of mortality and induce lasting protection) in 
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challenge tests and safety
3
 (evaluation of adverse effects such as mortality, organ adhesion, 
reduction of growth, behavioural changes and melanization on organs and tissues) [104]. In 
the development of new adjuvants for use in veterinary medicine, safety and efficacy are key 
issues, but a trade-off between the two is often the case; an increased safety profile for highly 
purified antigens often results in decreased immunogenicity of the vaccine [106]. The 
difficulty in balancing the two is well reflected in the low number of delivery systems 
commercialized both in veterinary and human medicine. For human vaccines, a major 
unsolved challenge in adjuvant development is to achieve a potent adjuvant effect while 
avoiding reactogenicity or toxicity. Even though many vaccine delivery system are in the 
pipeline, MF59 (squalene) and alum (Al(OH)3) are the only approved vaccine adjuvants in the 
majority of countries worldwide, where the latter still remain the standard [101]. In salmon 
vaccinology, substantial research has been devoted to finding alternatives to the mineral oil 
based adjuvant frequently used in injection vaccines. The reason for this has been ascribed to 
its highly reactogenic qualities causing adverse effects, where incidences of intra-abdominal 
lesions (organ adhesions), melanization in muscle, spinal deformities, reduced weight gain 
and long-term immunopathology (autoimmunity) has been reported [103;104;107-110] and 
the severity of the injections site reactions correlated to high expression of inflammatory 
markers [111]. Continued optimization of the vaccination regime and formulations may 
contribute to reduce the adverse effects typically seen for these vaccines [107;108;112]. 
However, many of the present generation of successful vaccines for salmonids are still based 
on oil adjuvanted delivery systems characterized by Th2-biased responses and high antibody 
titers [113] efficacious in preventing bacterial diseases [114;115], while efficacy against some 
intracellular pathogens remain inadequate.  
          In vaccine development, a key challenge is to understand the underlying differences 
between the immune responses induced by live replicating pathogens and the inactivated 
variants of the antigens used in vaccine formulations, especially in the context of vaccination 
against intracellular pathogens. In this regard, live attenuated and DNA vaccines have shown 
great prospective as alternative vaccines [116] as these vaccines rely on the natural 
invasiveness of the pathogen and the endogenous machinery of the host cells, respectively. 
They appear to offer significant potential for the induction of Th1-biased/CTL responses 
which have been one of the challenges faced with conventional oil based adjuvants. However, 
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the safety of live attenuated and DNA vaccines for use in fish is more a concern than their 
efficacy due to the risk of reversion to virulence and e.g. the integration into chromosomal 
DNA, respectively [117;118]. Nevertheless, a DNA vaccine
4
 against infectious 
haematopoietic necrosis virus (IHNV) and the use of Arthrobacter davidanieli as a live 
vaccine against Renibacterium salmoninarum and Piscirickettsia salmonis (causative agents 
for bacterial kidney disease (BKD) and salmonid rickettsial septicaemia (SRS), respectively)) 
have been approved for use on salmonids in the North American markets [21;119;120]. Much 
research has been devoted to bias the immune responses of inactivated vaccines towards 
induction of CTL effectors and furthermore identify safe alternatives that may contribute to 
reducing the use of oil-based adjuvants in salmonids and other teleosts, including a range of 
TLR ligands/immunostimulants [121-123] and novel carrier systems [124-128]. In the attempt 
to design the ideal vaccine (Table 2) balancing efficacy and safety, it remains to be seen if the 
novel adjuvants currently being explored will be implemented as a replacement or a 
complement to the oil adjuvanted vaccine delivery system so widely used in aquaculture.  
 
ADMINISTRATION OF FISH VACCINES 
          Vaccination of fish in aquaculture is performed by immersion (dipping in a diluted 
vaccine solution), injection (preferably intraperitoneally, but intramuscular for DNA vaccines) 
or by oral administration through feed [129]. The great advantage with oral administration of 
vaccine antigens is the reduced fish handling (including transport and sedation), however this 
method falls short due to lack of control over the dosage each individual fish receives and that 
antigens are prone to degradation before reaching the immune sensitive areas of the gut [130]. 
For salmonids, immersion vaccination is mainly used during the early life-stages just after 
reaching an immunocompetent size (0.5-1 g), and it allows for mass vaccination at a stage 
when injection is made difficult due to the small fish size [131]. Although both immersion 
and injection vaccines at present are integrated as part of the production routines in salmon 
aquaculture, oil-adjuvanted injection vaccines administered to parr of salmonids (about 30-50 
g) are recognized as the most efficacious route of administration for disease protection in 
larger production animals [129]. For high value species such as salmon and rainbow trout, 
injection vaccines are cost effective and represent a potent alternative as they allow the use of 
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 Information retrieved from http://www.ah.novartis.com/aqua/en/index.shtml (04.12.2011) 
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Table 2. Properties of an ideal vaccine [132]. 
 Life-long immunity 
 Broad protection against all variants of an organism 
 Prevent disease transmission 
 Induce effective immunity rapidly 
 Effective in all vaccinated subjects 
 Require few (ideally one) immunization to induce protection 
 Preferably not administered by injection 
 Cheap, stable and safe 
 Transmit maternal immunity to the fetus 
 
 
adjuvants and administration of predictable antigen doses in each vaccinated animal [117]. 
However, manual injection of vaccines in fish is considered labour intensive (2500-3000 
fish/vaccinator/hour) and the handling stressful for the animal. As a consequence, most 
modern injection vaccines are multivalent containing antigens from up to seven pathogens
5
 in 
a single injection and more effective automated vaccination machines capable of handling 





PLGA polymers and polymeric constructs 
  Because of their ease of manufacturing and desirable characteristics, biodegradable 
synthetic polymers such as PLGA have been the focus of extensive research for several 
decades. The American Food and Drug Administration (FDA) has approved the use of PLGA 
in human and veterinary medicine, and currently it is utilized in a range of biomedical 
products such as sutures [133], controlled pharmaceutical delivery matrices [134;135] and 
temporary orthopedic fixtures [136]. The use of PLGA as matrix for injectable microparticles 
was developed during the 1980s [127;137-141], and since then, research addressing the 
application of microparticles for delivery of therapeutic and prophylactic drugs, including 
antigens and immunomodulators has accelerated considerably. A recent trend in PLGA 
vaccinology has, however, been to construct particles in the nanometer size-range in an 
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 Information retrieved from www.pharmaq.no/products/  (06.11.2011). 
6
 Information retrieved from http://www.maskon.no/pages/vaksine.html (30.11.2011) 
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attempt to mimic pathogens and improve vaccine delivery targeted for APCs with the 
objective of inducing Th1-polarized responses [142].  
 
TECHNIQUES USED TO PREPARE PLGA PARTICLES  
          There are three commonly used techniques to prepare nano- and microparticles of 
PLGA; coacervation, spray-drying and the double emulsion solvent evaporation/extraction 
method [140;143-146]. All employ a similar first step, where antigen in an aqueous phase is 
emulsified in an organic solvent to yield a water-in-oil (W1/O) dispersion [147]. In the further 
process, the coacervation method involves several stages of polymer desolvation and 
hardening to form the solid particles, while spray-drying atomizes the particles in a flow of 
drying air at slightly elevated temperature. The most frequently used technique for antigen 
entrapment and vaccine preparation is the double emulsion solvent evaporation/extraction 
method wherein poly (vinyl alcohol) (PVA) is the most employed stabilizing agent since it 
forms particles of relatively small size and uniform size distribution [148-153;153-156]. The 
reader is referred to Figure 2 for further details on the method of particle preparation, 
exemplified with formulation parameters used in the work presented in this thesis (papers I-
IV). After final preparation, particles are lyophilized (freeze dried) to increase their shelf-life, 






                                        Figure 1. PLGA particles about 1-2 µm in diameter embedded 






Figure 2. Overview of the double emulsion solvent evaporation/extraction-procedure used to prepare of PLGA 
and PLA particles. Pictures and illustrations by Fredriksen 2011. 
 
QUALITIES OF PLGA POLYMERS IN VACCINES 
          Various qualities of the PLGA polymer may influence particle degradation and drug 
release and should therefore be considered in vaccine design. PLGA is a copolymer 
synthesized by random ring-opening copolymerization of two different monomers, the cyclic 
dimers (1,4-dioxane-2,5-diones) of glycolic acid and lactic acid (Figure 3). During 
28 
 
polymerization, successive monomeric units are linked together by ester linkages, yielding a 
linear, amorphous aliphatic polyester product [157]. In general, PLGAs are thermoplastic 
synthetic polyesters with glass transition temperature (Tg) above 37
o
C [158], hence they are 
glassy in nature and have a fairly rigid chain structure which gives them significant 
mechanical strength to be formulated as drug delivery devices [159;160]. For drug and 
antigen delivery, amorphous DL-PLGA (poly (DL-lactide-co-glycolide) acid) and DL-PLA 
(poly (DL-lactide) acid) has the preferred polymer stereochemistry because antigens are 
homogenously dispersed within these polymeric matrixes [161]. Furthermore, for preparation 
of vaccines mainly polymers with LA:GA monomer proportions ranging from 50:50 to 100:0 
has been utilized [147]. In this context, the use of PGA (poly (glycolic) acid) is limited due to 
its lack of solubility in appropriate solvents for drug loading [162]. Of the two monomers 
lactic and glycolic acid, the former is more hydrophobic, thus is absorbs less water and 
subsequently degrades more slowly [137;138], which makes lactide-rich PLGA particles less 
prone to degradation. However, exceptions to this rule are the co-polymers with 50:50 ratio 
where the fastest degradation rate is observed due to the amorphous nature of the polymer 
[163]. Together with the great safety and tolerability profile seen for PLGA in biological 
systems [164], the possibility to vary LA:GA ratio in particle constructs is a key feature for its 
use as a vaccine delivery system as it allows for tailored design of vaccines with predictable 
antigen release kinetics [165]. Furthermore, surface potential (ζ potential) and functional 
groups are two important physiochemical characteristics of particles in vaccine design as they 
may influence cellular uptake and tissue distribution, which will be addressed later.  
 
PLGA DEGRADATION 
          Polymer biomaterials can be divided into two main classes according to their lifetimes; 
namely biostable and biodegradable. The latter class includes PLGAs and are defined as 
polymers in which the degradation is at least mediated by a biological system [162]. PLGA is 
generally considered to degrade by non-enzymatic, autocatalytic cleavage of the ester 
linkages through spontaneous hydrolysis. This process is often referred to as a bulk erosion 
mechanism [166] and degradation takes place throughout the whole polymer matrix. During 
the first phase of hydrolysis the molecular weight of the polymer decreases significantly due 
to continuous cleavage and solubilization of low molecular weight fragments. At this stage no 
monomer products are formed and the construct still retains its original shape [167]. The 
middle phase (erosion or dissolution) of degradation is characterized by a rapid loss of mass 
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and formation of soluble oligomeric and D,L-lactic and glycolic acid monomers. In this phase 
the acidic microenvironment autocatalyze the further degradation. Complete polymer 
solubilization occurs when soluble oligomers are fragmented to soluble monomers [159]. 
Therefore, in addition to the LA content in the polymer, increased molecular weight 
contributes to extend the period (alter degradation behaviour) until complete polymer 
degradation occurs, an attribute that may be used in particle design to sustain antigen delivery 
[161]. PLGAs are known to be highly biocompatible and non-toxic [168], and after 
breakdown in the Kreb’s cycle complete removal of the moieties (lactic and glycolic acids) 
from the body occurs through the respiratory route as carbon dioxide [169] or via excretion in 
the kidneys or the liver as carbon dioxide and water [159]. 
 
DRUG RELEASE FROM PLGA PARTICLES 
PLGA particles either encapsulate drugs (in this context antigens and immunomodulators) or 
carry them on their surface through adsorption or covalent linkage [166]. Drug release from 
PLGA particles is most often assessed in vitro by incubation in a buffered aqueous solution, 
preferably at neutral pH. During incubation the encapsulated drugs are released into the 
surrounding buffer and successive sampling followed by analysis provides a picture of the 
release kinetics from the particles. For this purpose the bicinchoninic acid protein 






Figure 3. Chemical structure and biodegradation products of poly (lactic-co-glycolic) acid. The letters x and y 
denotes the ratio of lactic and glycolic acids in the polymer chain, respectively, hence a polymer with an equal 
number of the two monomers would be designated PLGA 50:50 (picture from [171]). 
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used methods. In the early phase of particle degradation, release of the entrapped drugs 
mainly occurs via diffusion in the polymer matrix, while release is mediated by a combination 
of diffusion and degradation of the polymer itself during the later stages [172]. Upon 
dispersion of particles in an aqueous solution, drugs absorbed to or near the surface are 
dissolved and diffuse out into the surrounding medium within a few hours or days, an event 
referred to as burst release [147;151;173]. Further release from the particles depends on 
particle porosity and hydrophilicity, as well as molecular interaction forces between polymer 
and drug [144;151;156]. In porous and hydrophilic particles there are less antigen-polymer 
affinity which facilitates water penetration into the particles while antigen diffuses out of the 
matrix [147]. Conversely, particles with dense cores, strong polymer-antigen interactions or a 
matrix of a hydrophobic polymer that restrict water uptake and subsequently pore formations, 
may have a lag phase with slow antigen release kinetics [147;151;156].  
Theoretically, a reduced particle size would lead to increased surface area to volume 
ratio, resulting in a large area for hydrolysis to find place and therefore accelerated drug 
release. However, opposing results have been put forward suggesting that the degradation 
kinetics on the particle surface and in the core follow different patterns [151;174], 
emphasizing that the degradation of PLGA particles and preservation of drug stability (e.g. 
important epitopes on antigens) are complex events where release conditions such as 
temperature [174], residual surfactant (PVA) [153], additives/excipients (e.g. poly ethylene 
glycol) [175;176] and pH [177], in addition to particle morphology (size, porosity) should be 
considered when evaluating the polymer degradation and drug release. Drug/antigen stability 
during particle preparation and degradation/drug release is outside the scope of this text and 
the reader is referred to other literature for further reading on this subject [178].        
 
CELLULAR UPTAKE OF PLGA PARTICLES 
          To achieve protective immunity from vaccination with inactivated vaccines it is 
required that the exogenous antigens are taken up, processed and presented by APCs. Uptake 
of antigens, immunomodulators and their carrier system by APCs is dependent on properties 
such as size, surface charge, shape and their hydrophobic/hydrophilic qualities, in addition to 
receptor interactions [179]. In comparison to emulsions, ISCOMs, TLR agonists and 
saponins, PLGA and liposome particles are considered inert depot forming carriers, unless 
they have a specific composition or carry immunostimulants [92;180].  
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The cellular uptake of nano- and microsized particles of PLGA has been well 
documented in macrophages and DCs [181-185] as well as epithelial cells [148;186] and 
vascular smooth muscle cells [187] in mammals. Depending on their size, particles may be 
incorporated in APCs via phagocytosis (0.5-10 µm), fluid phase (macro-) pinocytosis (0.5-5 
µm) or clathrin-coated pits (˂ 200 nm) [188;189]. Efficient internalization of small particles is 
assumed to be attributed to the comparable size particle carriers have to the pathogens the 
immune system has evolved to combat [190]. The upper limit for particle phagocytosis by 
APCs is regarded to be in the range of 5-10 µm in diameter. Moreover, particles possessing 
diameters of 2-3 µm have been shown to exhibit maximal attachment and uptake [191] while 
500 nm have been suggested as the lower cut-off size for efficient phagocytosis [192;193]. As 
the size of particles changes from nanometer to micrometer size within the range for cellular 
uptake, a drastic reduction in uptake of particles is observed [186;194-196]. A study by Desai 
et al [195] revealed a 2.5 and 6 fold greater uptake (based on weight) of 0.1 µm diameter 
particles compared to particles of 1 µm and 10 µm, respectively. Similarly, in terms of 
number, the uptake of 0.1 µm diameter particles was shown to be about 3 000 and 7 000 000 
times greater than the 1 µm and 10 µm counterparts, respectively [195]. Furthermore, 
efficiency of nanoparticle uptake is known to be influenced by the incubation time and 
particle concentration [182] with a steady state of uptake being reached within 1-2 hours of 
incubation [195;197]. Comparing high (37
o
C) and low (4
o
C) incubation temperatures have 
shown that higher temperatures are favourable for particle uptake [195].    
In addition to particle size, surface potential (often referred to as zeta (ζ) potential) is 
important for particle uptake. It is acknowledged that particles with primary amines at the 
surface generally undergo larger uptake compared to those having negatively charged sulfate, 
hydroxyl or carboxyl groups. Hence, positively charged (cationic) particles have a higher rate 
of cell uptake compared to negatively charged (anionic) or neutral formulations, while 
charged particles in general are more attractive for uptake compared to neutral particles [198-
201] which may be attributed to the nonspecific electrostatic interaction between cells and 
carriers. Moreover, hydrophobic microparticles and lipophilic nanoparticles have been shown 
to be more susceptible to phagocytosis than their hydrophilic counterparts [202]. 
The lag phase in the degradation model for PLGA particles is considered to be one of 
the advantageous for their use as a vaccine delivery system. The slow degradation rate hinders 
early release of the immunogenic cargo before the particles are internalized in APCs, in 
addition to reducing the systemic distribution of entrapped molecules [171]. In mice, the site 
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of administration has been shown to significantly affect the type of cells that internalize 
particles. Particles of PLGA are mainly taken up by DCs following intradermal [183] or 
subcutaneous [203] administration, whereas macrophages have been found to be the 
predominant cells internalizing particles from the peritoneal cavity [183]. Figure 4 shows 
scanning electron microscopy photos taken during uptake of PLGA particles (diameter of 
about 1-2 µm) in ex vivo adherent cells (presumably macrophages) isolated from Atlantic 
salmon head kidney. The intracellular fate of particles after uptake in APCs is, however, still 
poorly understood and debated [204], but particle delivery has been demonstrated to result in 
MHC class I and II processing pathway of antigens, as summarized by Hamdy et al [171]. 
Nanoparticles have been shown to colocalize with early endosomes short time after uptake 
and it is generally acknowledged that the increasingly acidic endosomal compartments in 
APCs will accelerate PLGA degradation resulting in release of the encapsulated cargo, and 
furthermore, for efficient cross-presentation (MHC I pathway) to take place, either the 
encapsulated antigens or the PLGA particles have to enter the cytoplasm [205]. In a 
frequently cited study by Panyam et al [206] it was suggested that a reversal of the surface 
charge (from anionic to cationic) of particles in the acidic endo-lysosomal compartment 
causes the particles to interact with the endo-lysosomal membrane resulting in rapid escape of 
the particle into the cytosol [206]. By cytosol extraction, Shen et al [207] confirmed that 
antigen delivery via PLGA particles in fact increases the amount of exogenous antigens that 
escape endosomes and enter into the cytosol. However, other studies have demonstrated that 
particles may persist inside the early endosomes for up to 15 days suggesting that particle 
hydrolysis takes place in this compartment [208]. In a recent study by Schliehe et al [204], 
electron dense inorganic nanocrystals were encapsulated in PLGA microparticles to study 
their intracellular localization. Lysosomal storage of PLGA particles was found and the  
  
Figure 4. Uptake of PLGA microparticles (MPs) (~1 µm) in adherent ex vivo head kidney leukocytes from Atlantic salmon 
viewed by scanning electron microscopy (SEM, 20.0 kV, magnitude 6000x). Scale bar 2 µm. (A) Untreated adherent head 




authors concluded that cross-presentation only occurs after translocation of the protein, but 
not the particles, from the phagolysosomal compartment into the cytosol [204]. Irrespective of 
intracellular degradation and localization, comprehensive research point to the fact that 
particulate antigen delivery favours extended antigen presentation by APCs, which will be 
addressed in a later section. 
 
ANTIGEN DEPOT AND BIODISTRIBUTION OF PLGA PARTICLES  
          For the purpose of antigen delivery, particle size and qualities such as surface charge 
may be important determinants to predict antigen location and kinetics. Due to their large 
size, microparticles of more than 5-10 µm are unable to relocate or be transported as 
intracellular cargo [209]. They will therefore form extracellular depots at the injection site 
from where they may slowly release their content. To the contrary, nanoparticles may be re-
localized via the systemic circulation following administration, either as cargo in cells or by 
permeating biological barriers [210]. Once in the bloodstream, particles may interact with 
plasma proteins and blood components [198] and rapidly become sequestrated by the 
mononuclear phagocytic system. Intravenously injected particles have been shown to 
accumulate in the liver or spleen [175;211;212], whereas oral delivery has demonstrated 
distribution to liver, kidney, heart, brain, lungs and spleen [168]. After intramuscular 
administration, microparticles have been found in lymph node residing CD11
+
 APCs for up to 
120 days [208].  
          Grafting, conjugation or absorption of hydrophilic polymers, most notably poly 
(ethylene glycol) (PEG) is a surface functionalization that may be used to increase residence 
time in blood, reduce non-specific distribution or target cells/tissues with targeting ligands 
[213]. It has been demonstrated that the so-called PEGylation may drastically reduce uptake 
in the liver, whereas uptake in the spleen is increased [214]. Similarly, reduced uptake has 
also been proposed to come as a result of residual PVA giving higher hydrophilicity of the 
particle surface [153;215]. Hence, by altering surface properties it is possible to avoid hepatic 





PLGA PARTICLES AS VACCINE ADJUVANTS 
          The adjuvant properties of PLGA particles is quite complex as it acts on several levels, 
including some which have already been touched upon in previous sections. In general, the 
uptake of antigens and immunostimulants by APCs is known to be favored by delivery in a 
particulate form rather than soluble [216]. Particles can furthermore protect the antigen from 
premature proteolytic degradation [217] and may serve as antigen vehicles and depots both 
after injection and oral delivery [218;219]. In therapeutic and prophylactic immunology, a 
wide of range of immunostimulants and antigens have been encapsulated or absorbed to 
PLGA particles, including TLR agonists (e.g. LPS [220], MPLA [94;142], CpG [221-224] 
and poly (I:C) [223;225]) or other immunostimulants (e.g. β-glucan [93;226]) alone or in 
combination with antigens (see review by Hamdy et al [171]), whole viral particles (paper III, 
[227]), bacterial vaccines (particularly against tetanus [176;228-237], recombinant proteins 
[238] and plasmid DNA [208;239].      
 PLGA particles are known to increase the potency of a vaccine formulation [233;240]. 
By the use of particle delivery of antigens, improved cytosolic delivery of antigens have been 
shown to increase the access of exogenous antigen to the MHC class I loading pathway, 
stimulation IL-2 secretion by T cells at 1000- and 10-fold lower concentration compared to 
soluble antigens and antigen-coated latex beads, respectively [207]. The rapid and extended 
uptake of particles seen for professional APCs also indicates a certain targeting function. This 
property can be further enhanced by co-encapsulating TLR-ligands or other targeting 
molecules [241]. By incorporation DC-specific targeting antibodies on PEG-coated PLGA 
nanoparticles, Cruz et al [217] demonstrated that antigen dependent T cell responses could be 
induced at 10-100 fold lower concentrations compared to non-targeted nanoparticles. As 
demonstrated by Newman et al [242], PLGA particles may also contribute to provoke and 
enhance responses even against poor immunogens.  
          In vivo studies using ‘empty’ particles have suggested that particles alone can serve as 
complete adjuvant systems without the addition of TLR ligands. In a study by Sharp et al 
[243] DCs were primed with particles of different sizes (430 nm, 1 µm, 10 µm and 32 µm) to 
establish the relationship between particle size and enhancement of inflammation. It was 
concluded that uptake of particulate adjuvants is required for their ability to promote IL-1β 
secretion and that 1 µm sized particles was more potent, followed by 430 nm, 10 µm and 32 
µm sized particles. Investigating TNF-α and IL-1β secretion in macrophages have shown 
similar distinct size-dependent responses [244] while adding of TLR ligands or antigens to the 
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formulations may further enhance innate responses by IL-6 and IL-12 production 
[142;245;246] and prolong as well as enhance antigen presentation [207;246].  
          In the search for efficient vaccines against tetanus (as summarized in e.g. [247]), a 
range of studies have investigated the ability of PLGA particles in generating humoral 
responses. Generally, these studies have demonstrated that PLGA particles may be more 
potent inducers of antibodies compared to alum [248], which is an adjuvant known to be a 
strong inducer of Th2 biased responses [79]. Additionally, combining the two has 
demonstrated a synergistic effect, seen as a more robust response both in terms of duration 
and titer levels [233;237]. Alum was found to promote increased attachment of particles on 
macrophage surfaces for a considerable period of time [249]. Designing PLGA particles with 
different release kinetics Kanchan et al [250] have suggested that slow and continuous release 
from polymer particles is critical in eliciting improved memory antibody responses from 
single point immunization [250]. Although conflicting data has been put forward [251], 
several studies have indicated that immune responses from micron-sized particles generally 
promotes humoral (Th2) responses while nanoparticles (˂1000 nm) promote cellular (Th1) 
responses [238;252-254]. Katare et al [254] compared humoral responses after administration 
of very large particles (50-150 µm), microparticles optimal for phagocytosis (2-8 µm) and 
small particles (˂ 2 µm). It was found that particles in the size range of 2-8 µm exhibited 
remarkable improvement in the antibody response, especially compared to the very large 
particles. From another study by the same authors, microparticles (also 2-8 µm in size) were 
found to elicit antibody titers without being phagocytosed, but merely non-specifically 
attached to the surface of macrophages due to their size and hydrophobic nature [255], which 
have also been suggested by others [196]. These findings were related to up-regulation of 
MHC class II molecules and promotion of IL-4 secretion, indicative of a Th2-type response. 
Several other studies have demonstrated high antibody levels using large particles 
[234;236;237;256;257] based on hydrophobic polymers [237]. It has been proposed that the 
continuous presence of antigen (e.g. released from large particles) results in high 
concentration of antigen in the extracellular space near APCs with the outcome of direct 
loading of antigens to the MHC class II pathway [258;259]. Antibody responses have also 
been found to depend on antigen load in microparticles (µg antigen/mg polymer). Katare et al 
[254] compared the ability of microparticles carrying high (28.2 µg/mg) and low (1.3 µg/mg) 
antigen loading to induce antibody responses. Microparticles with high antigen 
loading/particle resulted in higher and more sustained antibody titers, and with reference to 
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other reports [259;260], it was suggested that immune responses to antigens of exogenous 
origin is dependent on the concentration of antigen load inside the individual APC [254].   
          In the aforementioned study by Kanchan et al [255] it was moreover demonstrated that 
nanoparticles (compared to microparticles) induced higher levels of IFN-γ in concert with 
MHC class I up-regulation, suggesting that their nano-size contribute to intracellular 
phagosome-to-cytosol delivery of antigens and a Th1-type immune response. Similar strong 
Th1 and CTL biased responses with the use of PLGA particles have been shown in several 
studies, however the responses were not consistently based on nano-delivery. Shen et al [207] 
demonstrated potent CD8
+
 T cell responses (based on IL-2 secretion) and prolonged 
intracellular antigen presence when investigating cross-presentation after in vitro delivery of 
OVA in particles. Similarly, immunization with CpG ODN coated PLGA microparticles 
resulted in a pronounced IFN-γ secretion by splenic CD8
+
 cells in mice, as reported by [261], 
while Lee et al [223] showed enhancement in MHC class I restricted presentation of 
exogenous OVA when co-encapsulated with CpG ODN or poly (I:C), in addition to antigen-
specific CD4 and CD8 T cell proliferation. In a more comprehensive in vivo study by Heit et 
al [222], microspheres were loaded with a recombinant protein and CpG ODN. Results 
showed that these particles could trigger clonal expansion of antigen specific CD4 and CD8 T 
cells, and the potency was demonstrated by protective and therapeutic intervention. By co-
delivery of MPLA and OVA, Hamdy et al [262] confirmed these findings and demonstrated 
markedly increased in vitro CD8
+
 T cell proliferative responses (stimulation index above 
3000) and 13-fold increase in the in vivo expansion of CD4
+
 T cells. Furthermore, Schlosser 
et al [263] demonstrated that co-encapsulation, compared to administration in a mixed 
solution, may be superior in induction of protective immunity against viral infections. 
Together the studies presented in this section demonstrate that polymer-based particle 
delivery systems provide numerous ways to induce complementary humoral and cellular 





PREVIOUS WORK ON THE USE OF PLGA PARTICLES AS FISH VACCINES 
          Except for the papers presented in this thesis, there are to date only six research articles 
available on the NCBI (PubMed) database
7
 describing the use of PLGA particles as a vaccine 
delivery system in fish. These studies have addressed the use of PLGA as antigen/pDNA 
carriers for oral and parenteral (intraperitoneal) vaccine delivery in Atlantic salmon [264], 
rainbow trout (Oncorhyncus mykiss) [265;266], Japanese flounder (Paralichthys olivaceus) 
[127;239] and Indian major carp, Labeo rohita (rohu) [267].    
By oral delivery of encapsulated model antigens (human gamma globulin, HGG) to 
rainbow trout, O’Donnell et al [264] demonstrated that PLGA carriers results in higher 
antigen levels in serum compared to soluble (free) antigens. Furthermore, combining 
microparticles with 85:15 and 50:50 lactide:glycolide ratio, a pulsatile presence of HGG 
antigens in serum was observed at day 6 and week 5 post oral intubation. Using the same 
model antigen Lavelle et al [266] showed that antigens associated with microparticles (PLG 
50:50) increased the retention time, slowed the passage of antigen and protected the antigen 
from proteolysis through the digestive tract of rainbow trout. In addition more antigens were 
detected in the bloodstream. Although the results indicated that the antigen was partially 
protected during delivery, the subsequent antibody responses were found to be similar to the 
fish given soluble antigen. In a more recent study on rainbow trout, Altun et al [265] 
encapsulated the bacteria Lactococcus garvieae, presumably resulting in a vaccine with 
bacterial fractions embedded in the PLGA matrix. After oral vaccination and subsequent 
boost vaccinations, relative percent survival (RPS) was 63% and 44% at challenge 30 and 60 
days post vaccination, respectively. Following a boost vaccination at day 61 RPS values of 
71% and 64% was achieved at day 90 and 120, respectively. 
In a series of studies by Tian et al on Japanese flounder, PLGA nano- and 
microparticles was employed for oral administration of a plasmid (DNA) vaccine encoding 
the major capsid protein (MCP) from lymphocystis disease (LCD) virus [127;239]. 
Quantitative PCR and immunofluorescense analysis of tissues revealed that the MCP gene 
was present in gills, intestine, spleen, kidney, muscle, liver and heart 10 and 90 days post 
immunization with microparticles. Furthermore, a progressively increasing antibody 
production in sera was observed until 9 weeks post immunization, diminishing slowly 
                                                 
7
 Keywords: PLGA, fish, vaccine, vaccination, microparticles, nanoparticles. As a comparison, the keyword 
“PLGA” alone yielded 5043 search results, while “PLGA microspheres” and “PLGA nanoparticles” yielded 
1595 and 1140 search results, respectively. Information retrieved 05.12.2011  
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towards week 25 where MCP specific antibodies were no longer significantly different from 
the control [239]. In another study performed by the same researchers, oral vaccination with 
PLGA nanoparticles loaded with pDNA was followed by intramuscular challenge with 
LCDV. This study demonstrated that vaccination with PLGA/pDNA nanoparticles induced 
significant innate (e.g. lysozyme and respiratory burst) and adaptive (specific antibodies) 
responses in blood compared to the pDNA or the PLGA nanoparticles alone. More 
importantly, the vaccine contributed to drastically reduce the occurrence of nodules during 
disease progression and the immune parameters investigated could be correlated to the 
protection against the disease [127].   
Instead of oral delivery, Behera et al [267] administered a PLGA microparticle split 
vaccine carrying the outer membrane protein (OMP) of Aeromonas hydrophilia by the 
intraperitoneal route. In accordance with the work by Tian and Yu [268] non-specific and 
adaptive (specific antibodies) immune parameters in blood were found to be significantly 
higher in PLGA immunized Indian major carp compared to a Freund’s adjuvanted control at 




OBJECTIVES OF STUDY 
 
The last two decades, extensive studies have been performed involving PLGA/PLA 
nano- and microparticles as adjuvants in delivery of immunogenic agents. The current study 
on the use of this antigen delivery system in Atlantic salmon was motivated by the 
advantageous prospects polymeric particle have demonstrated as single shot multiple dose 
vaccines and their ability to induce immune responses against intracellular pathogens. This 
study aimed to characterize some of the adjuvant properties PLGA/PLA nano- and 
microparticles may have in Atlantic salmon. 
 
The specific objectives were to:  
 
 Develop/establish a protocol on how to prepare and characterize nano- and micro 
sized PLGA and/or PLA particles for research purposes.    
 
 Explore innate and adaptive immune responses to polymeric particles in Atlantic 
salmon. 
 
 Investigate how particle properties such as size and molecular composition 
contribute to the antigen retention and biodistribution in Atlantic salmon. 
 
 Evaluate vaccine efficacy of PLGA nanoparticles in Atlantic salmon after 













ABSTRACT OF PAPERS 
Paper I  
Early immune responses in Atlantic salmon (Salmo salar L.) after immunization with 
PLGA nanoparticles loaded with a model antigen and β-glucan 
Polymeric nanoparticles (NPs) of poly (lactic-co-glycolic) acid (PLGA) possess adjuvant 
properties. To date, there are few studies exploring their application as antigen carriers for 
vaccination of fish. This study presents a preclinical assessment of the early innate and 
adaptive immune responses in Atlantic salmon following immunization with PLGA NPs. A 
model antigen (TNP-LPH) and an immunostimulant (β-glucan) were entrapped in NPs of 
300-400 nm either alone or in combination. Both the antigen and the β-glucan were efficiently 
entrapped (>50%) in particles and an antigen release study indicated particle stability up to 50 
days at 8°C. Spleen and head kidney were analyzed for pro-inflammatory markers (TNF-α, 
IL-1β, IL-8, C3a) and T cell cytokines, effector molecules and transcription factors (IFN-γ, T-
bet, GATA-3, granzyme A, IL-10, Foxp3) at mRNA transcription levels 2, 4 and 8 days post 
i.p. immunization. NPs alone were able to moderately up-regulate pro-inflammatory immune 
responses. Addition of immunogenic cargo, either an antigen or β-glucan generally increased 
the gene expression of pro-inflammatory markers, while administering both resulted in the 
highest gene expression. These findings were also reflected by concurrently increased levels 
of IL-10. Comparing the treatment groups injected with antigen and β-glucan co-administered 
either in NPs or FCA demonstrated that the magnitude of the acute pro-inflammatory 
responses was equal between the treatments or highest in the NP injected group. Although 
elevated expression of granzyme A in the NP injected groups (carrying antigen and/or β-
glucan) was observed, PLGA NPs were unable to induce T cell differentiation on mRNA gene 
expression levels, as increased levels of the indicating cytokines and transcriptions factors 
failed to occur. In conclusion, this study demonstrates that PLGA NPs have potential as an 





PLGA/PLA micro- and nanoparticle formulations serve as antigen depots and induce 
elevated humoral responses after immunization of Atlantic salmon (Salmo salar L.). 
 
Novel vaccine delivery systems are highly needed to improve the salmon aquaculture 
industry. Although particles of biocompatible polymers such as poly(lactic-co-glycolic acid) 
(PLGA) have long been considered promising candidates for delivery of immunogenic 
compounds, few studies have addressed their use as vaccine carriers in Atlantic salmon 
(Salmo salar L.). Investigating their ability to retain/depot antigen and induce time and dosage 
dependent adaptive humoral responses to immunization, we here present a basic study of the 
adjuvantic properties PLGA and PLA particles may have in salmon vaccines. A model 
antigen (human gamma globulin, HGG) was co-encapsulated with β-glucan in nanoparticles 
(<1000 nm) and microparticles (∼8 μm) of different chemical compositions. Atlantic salmon 
were immunized with (a) PLGA or PLA particle entrapped antigen (12 different treatment 
groups), (b) antigen and β-glucan in PBS, (c) an oil-based formulation or (d) nanoparticles 
(NPs) or microparticles (MPs) combined with the oil-adjuvanted formulation. ELISA analysis 
showed that NPs and MPs were capable of inducing elevated antibody responses at day 60 
and 75 post immunization, but the antibody levels were reduced at day 90 and 120. In 
contrast, oil-based formulations, either alone or in combination with NPs or MPs resulted in 
strong antibody responses at all sampling time points. Comparable dosage dependent increase 
in antibody responses was observed when administering antigen with β-glucan either in PBS, 
entrapped in NPs or MPs, or in an oil-adjuvanted formulation. However, as the antigen doses 
were increased, MPs and the oil-based formulation gave the strongest responses. Antigen 
presence in the blood, organ package/injection site, kidney, carcass and the whole body was 
quantified by radiotracing of I
125
-labelled HGG at day 7 and 36 post immunization. At both 
sampling time points, the highest radioactivity levels were measured from the whole-body and 
organ package/injection site in groups injected with MPs and oil-based formulations, 
indicating that these formulations resulted in superior antigen retention. Interestingly, NPs 
were found to accumulate in the kidney, a result that corroborated with in vitro uptake of NPs 







Comparison of vaccine efficacy for different antigen delivery systems for infectious 
pancreatic necrosis virus vaccines in Atlantic salmon (Salmo salar L) 
 
Two phenotypes of infectious pancreatic necrosis virus (IPNV) made by reverse genetics on 
the backbone of the Norwegian Sp strain NVI-015 (GenBank AY379740) encoding the 
virulent (T217A221) and avirulent (P217T221) motifs were used to prepare inactivated whole 
virus (IWV), nanoparticle vaccines with whole virus, Escherichia coli subunit encoding 
truncated VP2-TA and VP2-PT, VP2-TA and VP2-PT fusion antigens with putative 
translocating domains of Pseudomonas aeruginosa exotoxin, and plasmid DNA encoding 
Segment A of the TA strain. In general, Kaplan Meyer’s survival plots reflecting the post 
challenge survival percentage (PCSP) for the different vaccines showed that inactivated whole 
viral (IWV) vaccines conferred highest PCSP (PCSP=42-53) while nanoparticle, sub-unit 
recombinant vaccines and the DNA vaccine fell short of the IWV when tested in Atlantic 
salmon (Salmo salar L) postsmolts challenged with the highly virulent Sp strain NVI-015 
(TA phenotype) of IPNV. Antibody levels induced by these vaccines did not show phenotypic 
differences between the virulent and avirulent motifs for vaccines made with the same antigen 
dose and delivery system after 8 weeks of immune induction. Comparison of vaccine efficacy 
based on ability to prevent establishment of infection showed that fish vaccinated with less 
potent vaccines tend to get infected much earlier and yield to higher infection rates than fish 
vaccinated with highly potent vaccines after challenge. Ability of the virulent and avirulent 
motifs to limit the establishment of viral infection showed equal protection for vaccine 
phenotypes made of the same antigen dose and delivery systems. Prevention of tissue damage 
linked to viral infection was eminent in the more potent vaccines than the less protective ones. 
Hence, there still remains the challenge of developing highly efficacious vaccines with the 
ability to eliminate the post challenge carrier state in IPNV vaccinology. 
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Paper IV  
Optimization of formulation variables to increase antigen entrapment in PLGA particles 
 
Efficient antigen entrapment is a key factor in preparation of poly (lactide-co-glycolide) acid 
(PLGA) vaccines when the antigen is of short supply. This study presents a systematic 
approach in the testing of formulation variables during PLGA particle preparation. The 
objective was to optimize/increase antigen entrapment in particles when the antigen stock 
concentration was low. Some of the experimental variables tested were poly (vinyl) alcohol 
(PVA) concentration in the inner (W1) and outer (W2) aqueous phase, W1/oil (O) phase ratio 
and choice of organic solvent. The double emulsion solvent evaporation technique was 
applied to prepare PLGA particles with sonication as the emulsifying force. To measure 





). Our results demonstrated that a low PVA concentration in the inner 
aqueous (W1) phase was beneficial to achieve a high encapsulation efficiency of antigen. On 
the contrary, in the outer aqueous (W2) phase, a high PVA concentration favored antigen 
entrapment. We also demonstrated that decreasing the W1 to O/polymer ratio contributed to 
increased entrapment efficiency. Testing different organic solvents (ethyl acetate, 
dichloromethane and chloroform), either alone or in combination, revealed that using 
chloroform as solvent resulted in the highest encapsulation of antigen and the highest 
production yield. Some of the results presented in this work are in disagreement with well 
established formulation variables from previous studies.  
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Paper V  
Mapping uncertainties in the upstream: The case of PLGA nanoparticles in salmon 
vaccines 
 
The diversity of nanotechnologies and of the governance challenges that their applications 
raise calls for exploration and learning across different cases. We present an Upstream 
Oversight Assessment (UOA) of expected benefits and potential harms of nanoparticles made 
of a synthetic polymer (PLGA) to improve vaccines for farmed salmon. Suggested by Jennifer 
Kuzma and colleagues, an UOA may help identify and prioritise research needs, and it may 
support evaluations of the adequacy of relevant existing regulatory frameworks. In this work, 
the UOA approach is modified and supported with elements from the uncertainty analysis 
framework developed by Warren Walker and colleagues. Empirically, we draw on relevant 
available published literature and insights generated in an ongoing nanoparticle salmon 
vaccine project, in which one of the authors participates. Nanotechnologies have not 
previously been encountered in the regulatory context of fish vaccines, which in part raises 
unique challenges due to prospective large scale vaccine use in semi-open aquatic systems. 
Strengthened through cooperation between ELSA and technology researchers we found the 
UOA useful for an early mapping of benefits and concerns, and for identifying areas in need 
of further research prior to a nanoparticle based salmon vaccine is developed and taken into 
use. We consider our approach to represent one among several complementing initiatives that 
seek to contribute to early stage evaluations of possible negative side effects, broadly 











RESULTS AND GENERAL DISCUSSION 
          At the time this project was started, very little was known about the performance of 
PLGA particle vaccines in fish. Because of this, several fundamental questions regarding their 
adjuvant properties were sought answered, including their ability to be distributed to 
lymphoid organs and retain antigens, to induce innate and adaptive responses as well as safety 
and efficacy of the vaccine concept after immunization and challenge, respectively. As results 
have been discussed in detail in the included papers, the following text will mainly make a 
summary of the main findings and address matters of a more general significance.  
 
Establishment of a protocol for preparation of PLGA particles  
Of the three most utilized protocols to prepare PLGA particles [140;143-146], the 
double emulsion solvent evaporation (water-in-oil-in-water) method was chosen as it is a well 
established and well described method in scientific literature with respect to antigen and 
immunostimulant encapsulation. In design of vaccines for research purposes, the focus areas 
were to optimize/maximize entrapment efficiency of antigens and produce stable particles 
within predictable size ranges (~ 200-500 nm, 1-2 μm and 5-15 μm). During the establishment 
of the emulsification procedure in our laboratory, it was realized that some of the process 
variables described, and often cited in literature did not agree with the results obtained in our 
studies. By a systematic approach, process variables including (1) choice of organic solvent; 
(2) PVA concentration in the internal and external water phase; and (3) volume ratios were 
investigated with the sole aim to increase antigen entrapment in the particles. A general 
description of the methodology is cited in Figure 2, while results from the current work have 
been presented and discussed in paper IV. Key findings showed that the entrapment efficiency 
is highly dependent on PVA concentrations and that satisfactory production yields (> 70%) 
could be obtained using chloroform. More importantly, the observations presented in paper IV 
were implemented in the preparation protocols for the formulations used in paper I-III, where 
model antigens (TNP-LPH and OVA) and whole virus particles (IPNV) were successfully 
encapsulated. In paper I and II, antigen release studies were also included to determine 
particle stability. Although particles were made of PLGA and PLA with different chemical 
qualities (MW and LA:GA ratios) and different size ranges (˂1000 nm or ~8 µm), it was 
demonstrated that particles generally were highly stable for up to 120 days irrespective of size 
and chemical properties (paper II). However, entrapment efficiency and loading of antigens 
and β-glucan were consistently lower in microparticles compared to nanoparticles (paper II), 
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but incorporation of β-glucan did not alter the entrapment or release of antigen notably (paper 
I). In general, the released antigen mainly came as a result of a burst release in both studies, 
while further incubation revealed an extended lag phase that did not accelerate considerably at 
the selected temperature (8
o
C) and during the incubation time in the current studies. There 
were, however, considerable release kinetic differences between micro- and nanoparticles 
(paper II), probably due to release of surface bound antigens [147;151;173], particle 
associated PVA [153] and/or particle porosity [147], where the latter seemed plausible as high 
burst release may be coupled to low entrapment efficiency. Moreover, it is likely that antigens 
have escaped the PLGA matrix during solvent evaporation and particle hardening at 
preparation, thereby resulting in the lowered entrapment efficiency generally obtained in the 
microparticle formulations.  
Temperature has been demonstrated to be an important factor both for cellular uptake 
of particles [195] and in vitro release [174] of antigens. Further studies on the stability of 
PLGA particles designed for salmon should therefore include particle incubation at higher 
temperatures (37
o
C) to accelerate antigen release. This will stress test the formulations and 
provide stability results that are comparable to other studies where murine animal models 
have been simulated.    
  
Safety profile for PLGA nano- and microparticles 
          As summarized in paper V (Table 1) only a few publications exist on the use of PLGA 
particles in fish and none of them have addressed safety aspects. To the author’s knowledge, 
paper II is therefore the first to present safety data on the use of PLGA nano- and 
microparticles in fish. The Speilberg-scale [104] is well established for evaluating 
macroscopic side-effects in Atlantic salmon by scoring organ and tissue adhesions. Since 
nano- and microparticle formulations may display different retention characteristics at the 
injection site, it was expected that the various preparations could induce different side effect 
profiles. Thus, it was decided to score also melanin deposition and vaccine residues on a 
separate scale [269]. High incidence of particle residues has been found in the peritoneum and 
the incidence of adhesions shown to be linearly related to the particle size [210]. Kohane et al 
[210] also reported that nanoparticles resulted in fewer adhesions due to rapid clearance from 
the peritoneum, while high MW polymers induced more adhesion than low MW polymers did 
- irrespective of polymeric residues in the peritoneum. Immunization (paper II) was 
performed with length adjusted reusable medical needles with metal hubs to ensure vaccine 
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delivery in the peritoneum avoiding injection into surrounding tissues/organs. Furthermore, 
particles were formulated under sterile conditions, but no additional sterilization was carried 
out after the final step of freeze-drying prior to injection, as was reported by Kohane et al 
[210]. Nevertheless, our results demonstrated that PLGA and PLA nano- and microparticles 
in general caused fewer adhesions compared to the oil-emulsion, with scores under 1.0 for all 
groups. According to the Speilberg-scale a score of 1 is given when “very slight adhesions” 
are seen focused around the injection site, while 2 indicates “minor adhesions” where 
adhesions to the abdominal wall can be observed [104]. The side effects observed for the 
PLGA or PLA formulations in paper II could not be related to the MW of the polymer, as 
reported by others [210], but micro-sized particles generally caused more incidents of melanin 
in the peritoneal cavity possibly due to prolonged presence of particles. Even though this is 
indicative of an irritant effect [270], the findings presented in paper II suggest an excellent 
safety record for the use of PLGA and PLA particles in Atlantic salmon, which is in 
accordance with safety studies on the use of PLGA particles reported in other animal models 
[168]. However, in paper III and in an unpublished vaccine study where PLGA nanoparticles 
were used to vaccinate Atlantic cod against furunculosis (Aeromonas salmonicida), severe 
side effect were observed (but not systematically documented), as pointed out in paper V. 
From these observations as well as in accordance with the European Pharmacopeia for 
veterinary vaccines, it is obvious that the safety of PLGA vaccines should be evaluated both 
on the basis of antigen (origin and dose) and the species for which its use is intended. 
 
PLGA particles induce inflammatory responses in Atlantic salmon 
          A cardinal adjuvant property is the ability to initiate innate immune responses. 
Although PLGA particles are known to be highly biocompatible, their potency as vaccine 
delivery systems has been demonstrated in a range of previous studies (as reviewed in e.g. 
[135;251]). In paper I, expression of the pro-inflammatory cytokines TNF-α and IL-1β, the 
chemokine IL-8 and complement factor C3 was quantified on mRNA transcript levels in vivo 
after immunization with different combinations of antigen (TNP-LPH) and β-glucan either 
encapsulated or in soluble form. Freunds Complete Adjuvant (FCA) was used as a positive 
control because it is known to cause inflammation [271]. PLGA nanoparticles were generally 
able to induce pro-inflammatory responses equal to or higher than FCA. Additionally, co-
entrapment of antigens and β-glucan gave indications of an additive effect compared to 
injecting the substances separately (paper I), a finding that is in accordance with others 
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[222;261;263]. An interesting temporal difference was observed, with TNF-α expression in 
the spleen occurring earlier in the nanoparticle group (NP/antigen/β-glucan) compared to the 
oil-adjuvanted control group. Due to their small size and the fact that particles were injected 
suspended in PBS, a rapid systemic distribution of the particles should not be ruled out [210]. 
Coupled to the high levels of IL-1β and IL-8, it was speculated whether the early splenic 
expression of TNF-α reflected the presence of nanoparticles (paper I) as particulate antigens 
have been found to accumulate in the spleen in teleosts [10]. TNF-α is an important activator 
of macrophages in salmonids, resulting in increased phagocytosis and chemotaxis, as well as 
induction of IL-1β and IL-8 [4]. As nanoparticles failed to up-regulate genes related to 
adaptive immunity (discussed in the next section), but induced strong innate responses, an 
interesting approach would be to explore macrophage activity e.g. by IL-12 and MHC class I 
and II expression in future studies. Generally, incorporation of β-glucan in the PLGA particles 
indicated a certain ability of this immunomodulator to increase the potency of the 
formulation, as seen by up-regulation of all the innate markers. Together with the efficient 
entrapment of β-glucan in PLGA nanoparticles our results suggest that β-glucan should be 
further explored in the context of vaccine delivery using PLGA. 
 
Adaptive responses to PLGA particles  
          Adaptive responses were investigated at early (day 2, 4 and 8) and late (day 60, 75, 90, 
120) time points after immunization by Q-PCR analysis of central T cell genes (paper I) and 
ELISA analysis for detection of antigen-specific antibodies (paper II), respectively. In paper I, 
expression analysis of CD4
+
 T cell genes (Th1 (IFN-γ and T-bet), Th2 (GATA-3), Treg (IL-
10 and Foxp3) and (CTL (granzyme A)) were investigated. Based on the findings reported by 
others [205;207;222;223;238;248;255;261-263;272], it was hypothesized that nanoparticle 
formulations could increase endosomal escape of antigens and induce CTL responses 
(increased expression levels of granzyme A mRNA) and Th1-like responses detectable as 
increased IFN- γ and T-bet expression. However, none of the selected Th1 and Th2 genes 
were differentially expressed and only elevated levels of IL-10 and granzyme A were found. 
Taken together, the expression levels for these genes failed to reject the null hypothesis. The 
reason for the non-responsiveness obtained for the adaptive markers were not known, but 
generally it may be questioned whether the immunological load constituted by the vaccines 
was too low to induce such responses, whether sampling was performed too early after 
immunization, if the study design in terms of sampling size were too few for such responses 
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to be detected by QPCR or most importantly, if the formulation in itself would be able to 
induce such responses irrespective of the former points. As sequences for the transcription 
factors (GATA-3 [51], Foxp3 [53] and T-bet (registered on NCBI)) in salmon have been 
made available quite recently, no solid data has been presented on their regulation after 
immunization of fish. By gene analysis twelve weeks after vaccination, Mutuloki et al [111] 
reported of high expression of inflammatory markers and IL-17 (a potent mediator in delayed-
type reactions) in correlation to side effects, but genes reflective of Th1 and Th2 responses 
were not differentially expressed. In a study by Haugland et al [273], T cell receptor genes 
were found to comprise a higher proportion of the up-regulated genes at day 19 compared to 
analysis performed at earlier time points (day 2 and 8). For future studies, later sampling time 
points as well as larger sample sizes should be included to rule out the possibility of the non-
responsiveness being a question of inadequate study design.   
In paper II, nano- (˂ 1000 nm) and microparticles (~ 8 µm) made of polymers with 
different qualities (MW and LA:GA) were investigated for their ability to induce specific 
antibody responses. Coupled to a study on antigen retention, the work aimed to examine the 
potency, magnitude and duration of the antibody responses in comparison to a group 
immunized with antigen emulsified in FCA, which is a combination known to be a strong 
inducer of humoral responses. In the dose-response study, potency and magnitude of the 
antibody production was demonstrated to be significantly higher in groups immunized with 
PLA-microparticles or FCA at doses of 100 µg antigen per injection (Fig. 3 in Paper II), 
which is in accordance with other studies comparing particle size and antibody responses 
[254;255]. Furthermore, antibody responses were found to be at their highest 60-75 days post 
immunization in groups injected with particle formulations suspended in PBS, while they 
decreased towards day 120. To the contrary, groups immunized with FCA alone or carrying 
nanoparticles or microparticles showed increased antibody responses towards day 120, when 
they were at their highest. These findings underline the superior ability of oil-adjuvanted 
vaccines to induce strong humoral responses in fish [104]. In mice, PLGA and PLA particles 
are able to induce strong antibody responses based on their size [254;255] and hydrophobic 
nature [237], and it has been demonstrated that combining nano- and microparticles may 
further enhance the responses [237]. Since a broad range of formulations were used in paper 
II and none of them were able to induce durable/robust antibody responses compared to the 
oil-adjuvanted group, it could be questioned whether the adjuvant properties of PLGA/PLA 
particles in general are too weak to induce similar responses. However, before conclusions are 
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drawn, further studies on the effect particle stability and surface potential have on antibody 
responses should be carried out. 
 
Microparticles are superior to nanoparticles in serving as antigen depots  
          As the depot effect is considered an important adjuvant property of the oil-based 
formulations used in salmon vaccines, it was of particular interest to investigate the ability of 
PLGA and PLA particles in retaining antigens after immunization. For this purpose, an 
isotope labeled protein was encapsulated and injected intraperitoneally. Because nanoparticles 
were expected to be rapidly absorbed from the peritoneal cavity and possibly cleared from the 
body, as reported by others [210], sampling was performed at relatively early time points (day 
7 and 36) compared to other studies and what could be expected with respect to the depot 
abilities of the oil-formulation [103;274]. Results from paper II indicated that the overall 
depot effect of microparticles in fact was superior to nanoparticles, and the latter were found 
to accumulate antigens in the kidney. Polymer qualities such as MW and LA:GA are known 
to have an impact on the degradation kinetics of particles [138;139;151;218] and particles 
were therefore formulated using polymers with high and low MW and various proportions of 
lactic acid. During long-term in vitro incubation at 8
o
C, nanoparticles released less antigen 
compared to microparticles irrespective of the mentioned polymer qualities, and based on 
size, the in vitro stability of particles was reversely related to the antigen retention observed in 
vivo. In general, paper II demonstrated that qualities such as high MW of the polymer 
combined with particle sizes above the phagocytic range are significant factors to increase the 
ability of particle formulations to depot antigens.   
 
Vaccine efficacy of PLGA nanoparticles  
          In paper III, the vaccine efficacy of PLGA nanoparticles was evaluated in a challenge 
test with infectious pancreatic necrosis (IPN), and comparison was made to other vaccine 
delivery systems, including whole inactivated vaccines, sub-unit vaccines and a plasmid DNA 
vaccine. Efficacy was evaluated based on parameters such as ability to confer protective 
immunity and reduce virus dissemination during the infection period following cohabitation 
challenge. During the immune induction period, nanoparticles provoked high antibody 
responses compared to the other formulations. Post challenge virus re-isolation from blood 
and head kidney further demonstrated that infection was established later in nanoparticle 
vaccinated fish compared to the PBS injected control group. However, at onset of acute 
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mortality (day 21) infection rates were equal in the control and the nanoparticle vaccinated 
group, as assessed by immunohistochemistry. Furthermore, despite the fact that the 
nanoparticle vaccinated fish were able to hold back the virus infection, the survival rates 
presented as a Kaplan Meyer plot showed that the two nanoparticle vaccines (containing a 
homologous and a heterologous antigen) clustered with the PBS injected control group, 
indicating that nanoparticles were unable to confer immunity against IPN. Overall, the 
nanoparticle vaccinated group performed similar to the pDNA and the subunit vaccines, while 
the inactivated whole virus vaccines formulated in an oil-based adjuvant generally were 
superior to all the vaccines in the current study. However, efficacy obtained for the different 
vaccines are not directly comparable as antigen doses differed between the formulations. For 
the nanoparticle vaccines, this was due to limiting factors during preparation; high virus titers 
are needed in the stock solution (W1-phase) during nanoparticle preparation to yield high 
antigen loading in particles. Consequently, the antigen dose in the inactivated whole virus 
vaccine was 200x higher compared to the antigen dose found in the nanoparticle formulations. 
Unpublished results from studies run parallel to paper III have demonstrated that antigen dose 




          Factors such as size, surface potential and polymer composition are cardinal 
determinants for particle-cell interactions following PLGA vaccination and might be 
important in directing immune responses. Combining these factors with the possibility to co-
deliver antigens and non-particulate (receptor-based) adjuvants makes PLGA particles highly 
flexible in vaccine design. In the current studies, all these aspects have been considered 
(although in minor detail) and results have demonstrated that PLGA particles are able to 
induce strong innate responses and serve as antigens depots after immunization of Atlantic 
salmon. However, their long-term effect on the immune responses seems to be disadvantaged; 
antibody responses were only transiently up-regulated and the challenge test revealed poor 
immunity against an intracellular pathogen (all results are summarized in Figure 5).        
          The fact that microparticles served as excellent antigen depots without this being 
reflected in antibody responses raises an interesting question; why is the antigen present, but 
immunologically ignored? Moreover, nanoparticles were able to efficiently transport antigens 
to an important lymphoid organ and thereby increase the antigen load in a tissue with 
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abundant macrophage presence. Is this important for the resulting immune response, and if so, 
how can this quality be exploited to direct responses? As most of the studies presented here 
were performed in vivo, it was made difficult to point out exactly what particle qualities are 
favorable for induction of humoral or cellular responses in salmon. Further studies should 
address these matters on a more detailed level in vitro, aiming to characterize particles that are 
















Figure 5. A summary illustration combining all the in vivo results obtained in papers I-III. Pro-inflammatory 
responses (red lines) were found to be equally high in salmon immunized with particle formulations as after 
immunization with an oil-based formulation, however TNF-α was an exception due to time of induction (red 
dashed line). The antigen depot (blue lines) was generally better in fish immunized with the oil-based 
formulation. Microparticles demonstrated moderate depot effect, while nanoparticles had low depot abilities. 
Salmon immunized with PLGA generally had transient elevated antibody levels (green lines), whereas fish 
immunized with the oil-based vaccine demonstrated an increasing level of antibodies during the experimental 
period. The PLGA particle formulations had low scores on the Speilberg-scale indicating excellent safety (grey 
circle), while efficacy (yellow circle) after challenge with IPN was low. The oil-based formulation resulted in a 
slightly lower safety score, as well as moderate protection against IPN. Abbreviations: NP – nanoparticle, MP – 









 PLGA nanoparticles carrying antigens and immunomodulators are able to induce 
strong innate responses in Atlantic salmon. 
 PLGA particles induce elevated, but transient antibody responses after 
immunization. 
 PLGA nanoparticles were unable to induce protective immunity against IPN. 
 PLGA microparticles may serve as antigen depots at the injection site. 
 PLGA nanoparticles increase the antigen load in the head kidney. 
 PLGA particles made of polymers with high molecular weight are superior to low 
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